Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oxford BioMedica ( (GB:OXB) ) has shared an update.
Oxford Biomedica has announced the admission of 13,921,114 new Ordinary Shares to the Main Market of the London Stock Exchange, following a successful placing and subscription. This increases the company’s total issued share capital to 120,173,462 ordinary shares, impacting the total voting rights and potentially affecting shareholder notifications under FCA rules.
The most recent analyst rating on (GB:OXB) stock is a Hold with a £532.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s overall score reflects strong earnings call insights and positive corporate events, indicating strategic growth and leadership confidence. However, financial performance challenges and valuation concerns moderate the score.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience in viral vectors, OXB collaborates with leading pharmaceutical and biotechnology companies, providing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. The company offers advanced technologies for viral vector manufacturing and has facilities in the UK, France, and the US.
Average Trading Volume: 161,145
Technical Sentiment Signal: Buy
Current Market Cap: £531M
See more data about OXB stock on TipRanks’ Stock Analysis page.